Adaptive Biotechnologies Corporation (ADPT)

2.6000 -0.0100 (-0.38%) At close: 04:00PM EDT

Adaptive Biotechnologies Corporation

1165 Eastlake Avenue East
Seattle, WA 98109
United States
206 659 0067
https://www.adaptivebiotech.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 709

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Julie Rubinstein	President & COO	721.04k	N/A	1972
Dr. Harlan S. Robins Ph.D.	Co-Founder & Chief Scientific Officer	711.09k	N/A	1973
Ms. Stacy L. Taylor	Senior VP, General Counsel & Corporate Secretary	N/A	N/A	1960
Ms. Mary Pat Lancelotta	Senior Vice President of MRD BioPharma	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Corporate governance

Adaptive Biotechnologies Corporation’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 6; Board: 8; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.